Skip to main content

Advertisement

SpringerLink
Log in

Quality of Life and Adverse Effects of Olanzapine Versus Risperidone Therapy in Patients with Schizophrenia

  • Original Paper
  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the χ2 test and Student’s t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Philip S: Antipsychotic drugs, dopamine receptors, and schizophrenia. Clinical Neuroscience Research 1(1–2):53–60, 2001

    Google Scholar 

  2. Abi-Dargham A, Laruelle M: Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry 20(1):15–27, 2005

    Article  PubMed  Google Scholar 

  3. Michalopoulou PG, Shergill SS, Kapur S: New and old antipsychotics: What ‘effectiveness’ trials tell us. Psychiatry 7(11):443–446, 2008

    Article  Google Scholar 

  4. Kao YC, Liu YP, Chou MK, Cheng TH: Subjective quality of life in patients with chronic schizophrenia: Relationships between psychosocial and clinical characteristics. Comprehensive Psychiatry 52(2):171–180, 2011

    Article  PubMed  Google Scholar 

  5. Saarni SI, Pirkola S: Quality of life of psychiatric patients. Duodecim; laaketieteellinen aikakauskirja 126(19):2265–2273, 2010

    PubMed  Google Scholar 

  6. Galuppi A, Turola MC, Nanni MG, Mazzoni P, Grassi L: Schizophrenia and quality of life: How important are symptoms and functioning? International Journal of Mental Health Systems 4:31, 2010

    Article  PubMed  Google Scholar 

  7. Heinrichs DW, Hanlon TE, Carpenter WT: The quality of life scale—an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10(3):388–398, 1984

    Article  PubMed  CAS  Google Scholar 

  8. Ueoka Y, Tomotake M, Tanaka T, Kaneda Y, Taniguchi K, Nakataki M, et al.: Quality of life and cognitive dysfunction in people with schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 35(1):53–59, 2011

    Google Scholar 

  9. Song YY, Kim KR, Park JY, Lee SY, Kang JI, Lee E, et al.: Associated factors of quality of life in first-episode schizophrenia patients. Psychiatry Investigation 8(3):201–206, 2011

    Article  PubMed  Google Scholar 

  10. Cardoso CS, Bandeira M, Caiaffa WT, Fonseca JOP: Escala de qualidade de vida para pacientes com esquizofrenia QLS-BR: Adaptação transcultural para o Brasil. Jornal Brasileiro de Psiquiatria 51(1):31–38, 2002

    Google Scholar 

  11. Brasil MdSd: Aprova o componente especializado da assistência farmacêutica. Diario Oficial Uniao, p. 725, 2009

  12. Manual Diagnóstico e Estatístico de Transtornos Mentais—DSM-IV-TR-TM: ArtMed Porto Alegre, 2003

  13. Brasil Mdsd: Protocolo clínico e diretrizes terapêuticas—esquizofrenia refratária. In: CONASS (Ed) Brasília, 2002

  14. Human D: Declaration of Helsinki. Lancet 357(9251):236, 2001

    Article  PubMed  CAS  Google Scholar 

  15. Garcia-Navarro A, Gonzalez-Puga C, Escames G, Lopez LC, Lopez A, Lopez-Cantarero M, et al.: Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. Journal of Pineal Research 43(2):195–205, 2007

    Article  PubMed  CAS  Google Scholar 

  16. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 334:1–100, 1987

    Article  PubMed  CAS  Google Scholar 

  17. Carpiniello B, Mellino G, Pintore S, Puddu L, Pinna F: Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study. Clinica Terapeutica 162(4):331–341, 2011

    PubMed  CAS  Google Scholar 

  18. Cianchetti C, Ledda MG: Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison. Psychiatric Research 189(3):349–356, 2011

    Article  CAS  Google Scholar 

  19. Foussias G, Remington G: Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making. Canadian Journal Of Psychiatry Revue Canadienne de Psychiatrie 55(3):117–125, 2010

    Google Scholar 

  20. Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al.: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP). American Journal of Psychiatry 168(9):947–956, 2011

    Article  PubMed  Google Scholar 

  21. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y: Quality of life outcomes of risperidone olanzapine and typical antipsychotics among schizophrenia patients treated in routine clinical practice—a naturalistic comparative study. Journal of Clinical Psychopharmacology 24(6):582–591, 2004

    Article  PubMed  CAS  Google Scholar 

  22. Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D: The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. Journal of Clinical Psychiatry 67(9):1397–1403, 2006

    Google Scholar 

  23. Leão A, Barros S: As representações sociais dos profissionais de saúde mental acerca do modelo de atenção e as possibilidades de inclusão social. Saúde e Sociedade 17:95–106, 2008

    Article  Google Scholar 

  24. Kim YT, Kang BJ: A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. Human Psychopharmacology: Clinical and Experimental 19(4):265–269, 2004

    Article  CAS  Google Scholar 

  25. Haddad PM, Hellewell JSE, Wieck A: Antipsychotic induced hyperprolactinaemia: A series of illustrative case reports. Journal of Psychopharmacology 15(4):293–295, 2001

    Article  PubMed  CAS  Google Scholar 

  26. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al.: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry 164(3):415–427, 2007

    Google Scholar 

  27. Ciudad A, Alvarez E, Bousono M, Olivares JM, Gomez JC: Safety and tolerability of olanzapine versus risperidone: A one-year randomized study in outpatients with schizophrenia with prominent negative symptoms. Actas Españolas de Psiquiatría 35(2):105–114, 2007

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Morphology/Postgraduate Program in Morphological Sciences, Federal University of Rio Grande do Norte, Natal, Brazil

    Raimundo Fernandes de Araújo Júnior

  2. Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal, Brazil

    Vanessa de Paula Soares Rachetti

  3. Department of Biophysics and Pharmacology, Postgraduate Program in Pharmaceutical Sciences of Federal University of Rio Grande do Norte, Natal, Brazil

    Gerlane Coelho Bernardo Guerra & Aurigena Antunes de Araújo

  4. Department of Dentistry/Postgraduate Program in Collective Health, Federal University of Rio Grande do Norte, Natal, Brazil

    Maria do Socorro Costa Feitosa Alves

  5. Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal, Brazil

    Luiz Alberto Lira Soares

  6. Postgraduate Program in Pharmaceutical Sciences, Federal University of Pernambuco, Recife, Brazil

    Luiz Alberto Lira Soares

  7. Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain

    Antoni Serrano-Blanco

  8. Pharmaceutical Science, Federal University of Rio Grande do Norte, Natal, Brazil

    Katarina Melo Chaves & Susana Barbosa Ribeiro

  9. Hospital da Polícia Militar of Rio Grande do Norte, Natal, Brazil

    Antônio Filgueira Júnior

Authors
  1. Katarina Melo Chaves
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoni Serrano-Blanco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susana Barbosa Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luiz Alberto Lira Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerlane Coelho Bernardo Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria do Socorro Costa Feitosa Alves
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raimundo Fernandes de Araújo Júnior
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vanessa de Paula Soares Rachetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Antônio Filgueira Júnior
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aurigena Antunes de Araújo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aurigena Antunes de Araújo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaves, K.M., Serrano-Blanco, A., Ribeiro, S.B. et al. Quality of Life and Adverse Effects of Olanzapine Versus Risperidone Therapy in Patients with Schizophrenia. Psychiatr Q 84, 125–135 (2013). https://doi.org/10.1007/s11126-012-9233-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11126-012-9233-3

Keywords

Search

Navigation